A Phase I, Dose Escalation Study of Oral ASP8273 in Patients with Non-small Cell Lung Cancers with Epidermal Growth Factor Receptor Mutations.
Clinical cancer research : an official journal of the American Association for Cancer Research
Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Genes, erbB-1; Humans; Male; Midazolam; Middle Aged; Mutation; Piperazines; Piperidines; Protein Kinase Inhibitors; Pyrazines; Pyrrolidines
Yu, Helena A; Spira, Alexander; Horn, Leora; Weiss, Jared; West, Howard J.; Giaccone, Giuseppe; Evans, Tracey; Kelly, Ronan J; Desai, Bhardwaj; Krivoshik, Andrew; Moran, Diarmuid; Poondru, Srinivasu; Jie, Fei; Aoyama, Kouji; Keating, Anne; and Oxnard, Geoffrey R, "A Phase I, Dose Escalation Study of Oral ASP8273 in Patients with Non-small Cell Lung Cancers with Epidermal Growth Factor Receptor Mutations." (2017). Articles, Abstracts, and Reports. 1736.